Earlier today Novamind Inc. (NM : CSE) (NVMDF: OTCQB) (HN2: FSE) opened its sixth integrative psychiatry clinic. The “Murray Clinic” also serves as Novamind’s third clinical research site, further strengthening the Company’s capabilities for serving drug developers via multiple sites and access to a large patient population.
The Company anticipates 65,000 visits to its clinics this year.
Yaron Conforti, CEO and Director, “Bringing cost-effective and innovative psychedelic therapies to market requires a large base of diverse candidates and the expertise to safely and effectively run complex clinical trials in the right environment. We continue to build on our model’s proven track record through the expansion of our clinics and research sites, and we expect to scale this unique operating model into additional states in the near term.”
Sit back, relax and watch this powerful interview with Yaron Conforti, CEO and Director of Novamind.
Tags: COMPASS PATHWAYS, CSE, Field Trip Health Ltd., ketamine, MDMA, Psychedelic, Psychedelic Therapy, psychedelics